Madrigal Pharmaceuticals (MDGL)

• Market cap: $10.9B
• 1 day: 0.45%
• 5 days: 0.44%
• 1 month: -5.78%
• 3 months: -11.17%
• 6 months: 37.63%
• Year to date: -19.01%
• 1 year: 44.97%
• 5 years: 298.11%
• 10 years: 7,243.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528